Source chain
We combine SIC sector classification, SEC company coverage, and financial statistics into one industry profile.
Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
180 public companies · 180 exchange-listed
Source: SEC EDGAR XBRL filings and Sprytne sector aggregates. Updated 2026-03-29T05:56:57.120Z. The page is designed for comparative research, not investment advice.
Source: SEC EDGAR XBRL filings and Sprytne sector aggregates. Updated 2026-03-29T05:56:57.120Z.
Why this industry page is useful for search, retrieval, and sector benchmarking.
Source chain
We combine SIC sector classification, SEC company coverage, and financial statistics into one industry profile.
Retrieval model
The page surfaces the strongest sector signals first so Google and LLMs can jump directly into the right company graph.
Quality gate
Only sectors with real SEC-linked company coverage are published, and the page reflects the latest available source snapshot 2026-03-29T05:56:57.120Z.
Tiny provenance blocks keep this hub citation-friendly and easier for retrieval systems to chunk.
Sector core
SIC classification, SEC coverage, and benchmark stats define the sector identity layer.
Comparative layer
Top performers, state concentration, and related sectors give the page a strong internal comparison path.
Retrieval shape
Short structured blocks help Google and LLMs move from the sector overview into the right company graph.
180
Total Companies
180
Exchange Listed
158
Filed 10-K
25
States Represented
Total Sector Revenue
$94.11B
Aggregate of 101 companies with XBRL data
Avg Net Margin
-81.5%
Intensely competitive· Based on 101 filings
Sector Analysis · Sprytne.com
As of July 2026, the Biological Products, (No Diagnostic Substances) sector (SIC 2836) reports a combined revenue of $94.11B across 101 SEC-tracked entities. With an average net margin of -81.5%, this industry is classified as loss-making on average. AMGEN INC leads the sector with $36.75B in reported revenue. The data is derived exclusively from official SEC EDGAR XBRL submissions and reflects the most recently filed 10-K annual reports.
Data aggregated from SEC EDGAR XBRL submissions · Updated March 2026
| Rank | Company | Revenue | Net Income | Net Margin | vs Industry Avg |
|---|---|---|---|---|---|
| #1 | AMGEN INCAMGN | $36.75B | $7.71B | 21.0% | +102.5pp |
| #2 | GILEAD SCIENCES, INC.GILD | $29.44B | $8.51B | 28.9% | +110.4pp |
| #3 | BIOGEN INC.BIIB | $9.89B | $1.29B | 13.1% | +94.6pp |
| #4 | NEUROCRINE BIOSCIENCES INCNBIX | $2.86B | $478.6M | 16.7% | +98.2pp |
| #5 | EXELIXIS, INC.EXEL | $2.32B | $782.6M | 33.7% | +115.2pp |
| Industry Average | $931.8M | $87.5M | -81.5% | baseline | |
4D Molecular Therapeutics, Inc.
CIK: 0001650648 · DE · 10-K: 2026-03-18
Abpro Holdings, Inc.
CIK: 0001893219 · DE · 10-K: 2025-04-15
Acumen Pharmaceuticals, Inc.
CIK: 0001576885 · DE · 10-K: 2025-03-27
ADAPTIN BIO, INC.
CIK: 0001938571 · DE · 10-K: 2025-04-15
Adaptive Biotechnologies Corp
CIK: 0001478320 · WA · 10-K: 2026-02-26
ADMA BIOLOGICS, INC.
CIK: 0001368514 · DE · 10-K: 2026-02-25
Agentix Corp.
CIK: 0001603345 · NV · 10-K: 2025-07-16
AGENUS INC
CIK: 0001098972 · DE · 10-K: 2026-03-16
Agomab Therapeutics NV
CIK: 0002020932 · C9
AIM ImmunoTech Inc.
CIK: 0000946644 · DE · 10-K: 2025-03-27
Alector, Inc.
CIK: 0001653087 · · 10-K: 2026-02-25
Aligos Therapeutics, Inc.
CIK: 0001799448 · DE · 10-K: 2026-03-05
Allogene Therapeutics, Inc.
CIK: 0001737287 · · 10-K: 2026-03-12
Alpha Cognition Inc.
CIK: 0001655923 · A1 · 10-K: 2025-03-31
Alvotech
CIK: 0001898416 · N4
AMGEN INC
CIK: 0000318154 · DE · 10-K: 2026-02-13
ANAVEX LIFE SCIENCES CORP.
CIK: 0001314052 · · 10-K: 2025-11-25
Apogee Therapeutics, Inc.
CIK: 0001974640 · · 10-K: 2026-03-02
Aptose Biosciences Inc.
CIK: 0000882361 · A6 · 10-K: 2025-03-28
Arcellx, Inc.
CIK: 0001786205 · DE · 10-K: 2026-02-26
ARGENX SE
CIK: 0001697862 · P7
Armata Pharmaceuticals, Inc.
CIK: 0000921114 · WA · 10-K: 2025-03-21
Artiva Biotherapeutics, Inc.
CIK: 0001817241 · DE · 10-K: 2026-03-10
Atara Biotherapeutics, Inc.
CIK: 0001604464 · DE · 10-K: 2026-03-16
aTYR PHARMA INC
CIK: 0001339970 · DE · 10-K: 2026-03-05
Aura Biosciences, Inc.
CIK: 0001501796 · DE · 10-K: 2025-03-24
Autolus Therapeutics plc
CIK: 0001730463 · X0 · 10-K: 2025-03-20
Beam Therapeutics Inc.
CIK: 0001745999 · DE · 10-K: 2026-02-24
BIO-TECHNE Corp
CIK: 0000842023 · MN · 10-K: 2025-08-22
BioAtla, Inc.
CIK: 0001826892 · DE · 10-K: 2025-03-28
Showing 30 of 180 companies in this sector
Biological Products, (No Diagnostic Substances) is the SEC SIC category used to group companies with similar business models and financial reporting patterns.
The page is refreshed from the underlying SEC-driven company index on deploy and when the cached data changes.
Some companies do not have recent usable XBRL filings or do not expose enough data for every benchmark on the page.
Use them to compare leaders, spot high-margin companies, and move into the individual company pages for deeper analysis.